⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 22, 2018Journal of Allergy and Clinical ImmunologyOpen Access

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

These data support the long-term safety and efficacy of mepolizumab in patients with SEA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khatri et al. (2018) studied this question.

synapsesocial.com/papers/69d8c356ce048d2571bee224 https://doi.org/10.1016/j.jaci.2018.09.033

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabCohort Study · 2014 · 228 citations
2The safety of mepolizumab for the treatment of asthmaReview · 2017 · 30 citations
3Biomarkers for severe eosinophilic asthmaReview · 2017 · 228 citations
4Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic AsthmaRetrospective Study · 2018 · 93 citations